Clinical Trial Update: DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) Pathway [Phase 2]

View source ↗

Summary

Phase 2 DAYBREAK trial evaluating setmelanotide in participants with specific gene variants in the MC4R pathway for genetic obesity has completed; results were …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Monogenic Obesity
• Obesity

Drugs mentioned

• Setmelanotide (setmelanotide)

Snippet

Sponsor: Rhythm Pharmaceuticals, Inc. | Conditions: Genetic Obesity | Phase 2 | Status: COMPLETED | Results posted: 2024-10-24